共查询到20条相似文献,搜索用时 15 毫秒
1.
K. Anette Birkmeier MD Adnan Kastrati MD Robert A. Byrne MB MRCPI Heidrun Holle Stefanie Schulz MD Klaus Tiroch MD Sebastian Kufner MD Steffen Massberg MD Karl‐Ludwig Laugwitz MD Albert Schömig MD Julinda Mehilli MD 《Catheterization and cardiovascular interventions》2011,77(4):494-501
Objectives and Background : First generation drug‐eluting stents have shown differential efficacy in high‐risk patient subsets at one year. It is unclear whether these differences endure over the medium‐ to long‐term. We compared the five‐year clinical efficacy and safety of sirolimus‐eluting stents (SES) and paclitaxel‐eluting stents (PES) in a population of high‐risk patients. Methods : The patient cohorts of the ISAR‐DESIRE, ISAR‐DIABETES, and ISAR‐SMART‐3 randomized trials were followed up for five years and data were pooled. The primary efficacy endpoint of the analysis was the need for target lesion revascularization (TLR) during a five‐year follow‐up period. The primary safety endpoint was the combination of death or myocardial infarction (MI) after five years. Results : A total of 810 patients (405 patients in the SES group and 405 patients in the PES group) was included. Over five years TLR was reduced by 39% with SES compared with PES stent (hazard ratio [HR] 0.61; 95% confidence interval [CI] 0.44–0.85; P = 0.004). No difference was observed according to death or MI rates between the two groups (HR 1.10; 95% CI 0.80–1.50; P = 0.57). Definite stent thrombosis occurred in 0.2% (n = 1) in the SES group and in 1.6% (n = 6) in the PES group (HR 0.16; 95% CI 0.02–1.34; P = 0.12). Conclusions : In high‐risk patient subsets the lower rate of 12‐month TLR observed with SES in comparison PES is maintained out to five years. In terms of safety, although there was no difference in the overall incidence of death or MI, there was a trend towards more frequent stent thromboses with PES. © 2011 Wiley‐Liss, Inc. 相似文献
2.
Julia Ellert Evald Hj Christiansen Michael Maeng Bent Raungaard Svend Eggert Jensen Steen Dalby Kristensen Karsten Tange Veien Anders Bo Junker Lars Jakobsen Jens Aare Christian Juhl Terkelsen Johnny Kahlert Anton Boel Villadsen Hans Erik Btker Lisette Okkels Jensen 《Catheterization and cardiovascular interventions》2019,93(4):567-573
3.
4.
5.
Soon Jun Hong MD Moo Hyun Kim MD Kwang Soo Cha MD Hun Sik Park MD Shung Chull Chae MD Seung Ho Hur MD Hyeon Cheol Gwon MD Jang Ho Bae MD Do‐Sun Lim MD PhD FACC 《Catheterization and cardiovascular interventions》2010,76(7):924-933
Background : Three‐year follow‐up of major adverse cardiovascular event (MACE) (death, nonfatal myocardial infarction, target lesion revascularization) and the predictors of MACEs in diabetic patients after sirolimus‐eluting stent (SES) or paclitaxel‐eluting stent (PES) implantation have not been reported. Methods : Diabetic patients with de novo coronary lesions (169 patients with 190 lesions) were randomly assigned prospectively to either SES or PES. Results : Baseline characteristics were similar between the two groups. The rates of MACEs [5.9% (n = 5) in the SES vs. 9.5% (n = 8) in the PES Group, P = 0.374] and definite stent thrombosis [1.2% (n = 1) in the SES vs. 3.6% (n = 3) in the PES Group, P = 0.368] were similar in the two groups during the three‐year follow‐up. Multivariate logistic analysis showed that insulin treatment was the only independent predictor of MACE [odds ratio (OR) 8.60, 95% confidence interval (CI) 3.25–22.76, P < 0.001] and target vessel revascularization (TVR) (OR 9.50, 95% CI 3.07–29.44, P < 0.001) during the three‐year follow‐up. Conclusions : The rates of MACEs, TVR, and stent thrombosis during the three‐year follow‐up were similar in the SES and PES Groups. Insulin treatment was a main predictor of MACEs and TVR during the three‐year follow‐up after either SES or PES implantation. © 2009 Wiley‐Liss, Inc. 相似文献
6.
7.
Probal Roy MD Rebecca Torguson BS Teruo Okabe MD Tina L. Pinto Slottow MD Daniel H. Steinberg MD Kimberly Smith BS Zhenyi Xue MS Natalie Gevorkian MD Lowell L. Satler MD Kenneth M. Kent MD William O. Suddath MD Augusto D. Pichard MD Ron Waksman MD 《Catheterization and cardiovascular interventions》2007,70(2):167-172
Background : Sirolimus‐eluting stents (SES) and paclitaxel‐eluting stents (PES) both significantly reduce the need for repeat intervention compared to bare metal stents. Studies comparing the clinical outcomes of these stents in noncomplex subsets of patients and lesions demonstrate a similar safety and efficacy profile. The data for more complex subsets of patients and lesions remains conflicting. This study aimed to compare SES with PES in a selected population with a broad range of complex features. Methods and Results : The patient population consisted of 1,591 consecutive patients with complex features undergoing drug‐eluting stent (DES) implantation. In the SES group there were 1,095 patients (1,653 lesions) and in the PES group 496 patients (802 lesions). In‐hospital, 30‐day, and 12‐month clinical outcomes were compared between groups. No discernable difference in major adverse cardiac events (MACE) between SES and PES was detected at intermediate and longer‐term follow‐up (SES 22.4% vs. PES 20.5% at 12 months; P = 0.407). A trend toward increased angiographically documented stent thrombosis was observed in the SES group at both 3 and 12 months (SES 2.2% vs. PES 0.8% at 12 months; P = 0.051). When adopting the more inclusive definition of probable stent thrombosis, this trend was no longer seen. After adjusting for baseline differences between the two groups, there still remained no difference in MACE between SES and PES (HR 1.051 [CI 0.826–1.339] P = 0.685). The trend toward increased angiographically documented stent thrombosis in the SES group remained after adjustment for baseline differences (HR 2.836 [CI 0.968–8.311] P = 0.057). Conclusions : In a selected population with complex disease the rate of MACE was comparable between SES and PES, with higher overall rates of thrombosis and MACE compared to a noncomplex population. Thus, the focus should be directed to prevent late complications in this complex subset regardless of stent type selection. © 2007 Wiley‐Liss, Inc. 相似文献
8.
Comparison of 2‐year outcomes between zotarolimus‐eluting and everolimus‐eluting new‐generation cobalt–chromium alloy stents in real‐world diabetic patients 下载免费PDF全文
Tadashi Miyazaki MD Azeem Latib MD Vasileios F. Panoulas MD PhD MRCP Sakiko Miyazaki MD PhD MPH Charis Costopoulos MD Katsumasa Sato MD Toru Naganuma MD Hiroyoshi Kawamoto MD Hiroyuki Daida MD PhD Antonio Colombo MD 《Catheterization and cardiovascular interventions》2015,86(1):E11-E18
Background : To date, it remains unknown whether different types of new‐generation drug‐eluting stents have a differential impact on long‐term outcomes in diabetic patients. Methods and Results : In this historical cohort study (two Italian centers), we analyzed 400 diabetic patients with 553 coronary lesions treated with new‐generation CoCr zotarolimus‐eluting stents (R‐ZES: 136 patients, 196 lesions) or everolimus‐eluting stents (EES: 264 patients, 357 lesions) between October 2006 and August 2012. Primary endpoint was the occurrence of major adverse cardiac events (MACE) over a 2‐year follow‐up period. MACE was defined as all‐cause mortality, any myocardial infarction (MI) and/or target lesion revascularization (TLR). Multivessel revascularization, intervention for restenotic lesion and use of intravascular ultrasound were significantly higher in the R‐ZES group, whereas small stent (≤2.5 mm) deployment was significantly higher in the EES group. At 2‐year follow‐up, there was no significant difference in occurrence of MACE (R‐ZES vs EES: 22.8% vs 18.9%, P = 0.39). Similarly, no significant differences were observed in the composite endpoint of all‐cause mortality/MI (10.0% vs 10.3%, P = 0.86) or TLR (12.4% vs 7.4%, P = 0.11). Adjustment for confounders and baseline propensity‐score matching did not alter the aforementioned associations. Conclusion : After 2 years of follow up similar outcomes (MACE, all‐cause mortality/MI, TLR) were observed in real‐world diabetic patients, including those with complex lesions and patient characteristics, treated with R‐ZES and EES. © 2015 Wiley Periodicals, Inc. 相似文献
9.
Complex patients treated with zotarolimus‐eluting resolute and everolimus‐eluting xience V stents in the randomized TWENTE trial: Comparison of 2‐year clinical outcome 下载免费PDF全文
Hanim Sen Ming Kai Lam Kenneth Tandjung Marije M. Lwik Martin G. Stoel Frits H.A.F. de Man J. W. Louwerenburg Gert K. van Houwelingen Gerard C.M. Linssen Carine J.M. Doggen Mounir W.Z. Basalus Clemens von Birgelen 《Catheterization and cardiovascular interventions》2015,85(1):74-81
10.
11.
Ravi K. Ramana DO Adam Ronan MD Kevin Cohoon DO David Homan MD Jessica Sutherland MD Lowell Steen MD Jayson Liu MD Henry Loeb MD Bruce E. Lewis MD 《Catheterization and cardiovascular interventions》2008,71(7):886-893
Objective : To evaluate the long‐term clinical outcomes of patients undergoing percutaneous coronary intervention for saphenous vein graft (SVG) disease. Specifically, we compared clinical endpoints of patients who received sirolimus‐eluting stents (SES) versus bare‐metal stents (BMS) for SVG disease. Background : A recent small randomized‐controlled trial (RCT) reported increased mortality with the use of SES in SVG disease. Methods : We retrospectively identified patients who underwent SES placement for a SVG lesion(s) at our institutions over a 4‐year period. The procedural and medical records were reviewed to identify predetermined clinical outcomes. Results : 318 patients who underwent SES placement for a SVG lesion were identified. 7 patients were lost to follow‐up. 141/311 patients (45%) received SES, while 170/311 (55%) received BMS. At a mean follow‐up of 34 months, there was a reduction in target lesion revascularization (TLR) (7% vs. 14%, P = 0.07) without an increased risk of mortality (6% vs. 12%, P = 0.06) in patients who received SES compared to patients who received BMS. When compared to the recent RCT's SES patients at long‐term follow‐up, our SES patients had significantly less mortality; rates of myocardial infarction, TLR, target vessel revascularization, and major adverse cardiac events; and were more likely to be taking dual antiplatelet and statin medications. Conclusion : Our results support that SES used in SVG lesions result in a reduction in TLR without an increased risk of mortality, and therefore may be an equally safe and feasible technique for revascularization with excellent long‐term clinical outcomes. These patients may benefit from prolonged dual antiplatelet and statin medication regimens. © 2008 Wiley‐Liss, Inc. 相似文献
12.
13.
Rationale and design of amphilimus sirolimus‐eluting stents versus zotarolimus‐eluting stents in all‐comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial 下载免费PDF全文
Rik Rozemeijer MD MSc Mèra Stein MD PhD Peter Frambach MD Michiel Voskuil MD PhD Adriaan O. Kraaijeveld MD PhD Ramón Rodríguez‐Olivares MD Leo Timmers MD PhD Bruno Pereira MD Saskia Z. Rittersma MD PhD Pierfrancesco Agostoni MD PhD Pieter A. Doevendans MD PhD FESC Pieter R. Stella MD PhD 《Catheterization and cardiovascular interventions》2018,91(3):410-416
14.
Impact of total stent length after cobalt chromium everolimus‐eluting stent implantation on 3‐year clinical outcomes 下载免费PDF全文
Shoichi Kuramitsu MD Tomohiro Shinozaki MPH Hiroyuki Jinnouchi MD Takashi Morinaga MD Yohei Kobayashi MD Takenori Domei MD Yoshimitsu Soga MD Shinichi Shirai MD Kenji Ando MD 《Catheterization and cardiovascular interventions》2017,89(2):207-216
15.
Xavier Freixa MD Ali S. Almasood MD Sohail Q. Khan MD Rodrigo Wainstein MD Azriel Osherov MD Karen Mackie RN Peter H. Seidelin MD FSCAI Vladimír Džavík MD FSCAI 《Catheterization and cardiovascular interventions》2012,79(4):559-565
Objective: To compare the outcomes between paclitaxel‐eluting stents (PES) and sirolimus‐eluting stents (SES) for the treatment of drug‐eluting stent (DES) fracture. Background: DES fracture is considered as an important predictor of in‐stent restenosis (ISR). However, little data are available evaluating the optimal treatment for this complication of coronary stenting. Methods: From January 1, 2004 to December 31, 2008, patients with DES ISR treated with a second DES were identified and evaluated for stent fracture. Stent fracture was defined by the presence of strut separation in multiple angiographic projections, assessed by two independent reviewers. Target lesion revascularization (TLR) at 6 and 12 months were the primary end points. Results: Of 131 lesions with DES ISR treated with a second DES, we found 24 patients (24 lesions, 18.2%) with angiographically confirmed stent fracture. Of these, 20 patients (20 lesions) treated with either PES (n = 11/55%) or SES (n = 9/45%) were included in the study. TLR at 6 months occurred in 9% of patients treated with PES and 22% of those treated with SES (P = 0.41). After 12 months, TLR was 9% and 55.5%, respectively (P = 0.024). Conclusions: This study demonstrates a high incidence of stent fracture in patients presenting with DES ISR in need of further treatment with another DES. The suggested association between treatment of stent fracture‐associated DES ISR with PES as compared with SES, and better long‐term outcomes, is in need of confirmation by larger prospective registries and randomized trials. © 2011 Wiley Periodicals, Inc. 相似文献
16.
Robert Applegate MD James Hermiller MD Jerome Williams MD Paul Gordon MD Julie Doostzadeh PhD Sherry Cao MS Xiaolu Su MS Krishnankutty Sudhir MD Alexandra Lansky MD Charles Simonton MD Gregg Stone MD 《Catheterization and cardiovascular interventions》2010,76(5):644-651
Objective: To evaluate whether an everolimus‐eluting stent (EES) with thinner stent struts and polymer results in less periprocedural myonecrosis and adverse outcomes. Background: Higher periprocedural myocardial infarction (MI) rates have been reported with the TAXUS® EXPRESS2 paclitaxel‐eluting stent (PES) compared to the bare metal EXPRESS2® stent due to more frequent side branch compromise, presumably attributable to the thickness of the stent/polymer on the PES. Methods: In the SPIRIT III trial, we identified 113 patients in the XIENCE V® EES group and 63 patients in the TAXUS EXPRESS2 PES group who met the criteria of having a lesion with a jailed side branch (<2 mm diameter, and <50% stenosis). Two‐year clinical outcomes were evaluated. Results: A periprocedural increase in Creatine Kinase‐MB >1× upper normal level occurred in 9.0% of EES compared to 29.7% of PES patients with jailed side branches, P = 0.01. Through 2 years, major adverse cardiac events (MACE; cardiac death, MI, or target lesion revascularization [TLR]) occurred in 6.8% of EES and 19.0% of PES jailed side branch patients (P = 0.03), with numerically lower rates of MI (2.9% vs. 10.3%, P = 0.07) and TLR (3.9% vs. 10.3%, P = 0.17) in the EES group, with comparable rates of cardiac death (1.9% vs. 1.7%, P = 1.00). Conclusions: In this post‐hoc analysis of the SPIRIT III RCT, patients undergoing stenting of target lesions with jailed side branches with the thin strut and polymer XIENCE V EES compared to the thicker strut TAXUS PES had lower rates of MACE through 2 years due to fewer MIs and TLRs. © 2010 Wiley‐Liss, Inc. 相似文献
17.
Johannes Ruef MD MSC Hans Störger MD Franz Schwarz MD Jürgen Haase MD PhD 《Catheterization and cardiovascular interventions》2008,71(3):333-339
Background : In selected patient cohorts the polymer‐free rapamycin‐eluting YUKON stent (A) has demonstrated noninferiority compared with the polymer‐based paclitaxel‐eluting TAXUS stent (B). To test for equivalency in unselected real‐world patients with coronary lesions of various complexities, we retrospectively compared both stent designs. Methods : A total of 410 patients with symptomatic CAD were successfully treated with A (n = 205) or with B (n = 205). Baseline clinical characteristics, coronary lesion location, lesion length, and the number of stents implanted per lesion were equally distributed between the treatment groups. All patients underwent QCA‐analysis at baseline. Clinical follow‐up with assessment of MACE and noncardiac deaths was obtained at 30 days and 6 months. Results : Nominal stent diameter was 2.96 ± 0.38 mm in Group A vs. 3.05 ± 0.42 mm in Group B (P = 0.2); nominal length of stented segmentwas 22.97 ±13.0 mm vs. 23.63 ± 10.0 (P = 0.56). Analysis of MACE after 6 months resulted in one angiographically documented stent thrombosis causing MI in B (0.2%) vs. none in A. No other MI or cardiac deaths occurred in either group, while two noncardiac deaths in A (1.0%) were reported. Fifteen target lesion revascularizations (7.3%) were performed in A vs. 7 (3.4%) in B. Differences in study endpoints at 6 months did not reach statistical significance (P > 0.05). Conclusions : Up to 6 months after PCI of real‐world coronary lesions, there were no statistically significant differences in MACE between patients treated with the polymer‐free rapamycin‐eluting YUKON stent and the polymer‐based paclitaxel‐eluting TAXUS stent. © 2008 Wiley‐Liss, Inc. 相似文献
18.
19.
Five‐year follow‐up of polymer‐free sirolimus‐ and probucol‐eluting stents versus new generation zotarolimus‐eluting stents in patients presenting with st‐elevation myocardial infarction 下载免费PDF全文
Roisin Colleran MB BCH Sebastian Kufner MD Yukinori Harada MD Daniele Giacoppo MD Salvatore Cassese MD PhD Janika Repp MD Jens Wiebe MD Raphaela Lohaus MD Annalena Lahmann MD Simon Schneider MD Tareq Ibrahim MD Karl‐Ludwig Laugwitz MD Adnan Kastrati MD Robert A. Byrne MB BCH PhD for the Intracoronary Stenting Angiographic Results: Test Efficacy of Sirolimus‐ Probucol‐Eluting Versus Zotarolimus‐Eluting Stents Investigators 《Catheterization and cardiovascular interventions》2017,89(3):367-374
20.
Two‐year clinical outcomes of the NOBORI biolimus‐eluting stents versus XIENCE/PROMUS everolimus‐eluting stents in small vessel disease 下载免费PDF全文
Hiroyuki Jinnouchi MD Shoichi Kuramitsu MD Tomohiro Shinozaki MPH Takashi Hiromasa MD Yohei Kobayashi MD Takashi Morinaga MD Kyohei Yamaji MD Yoshimitsu Soga MD Shinichi Shirai MD Kenji Ando MD 《Catheterization and cardiovascular interventions》2016,88(5):E132-E138